News

“[Gene therapy may] dramatically reduce frequency of treatments.”

Socioeconomic factors have long been a looming issue in various health outcomes. A team of researchers from Shanghai Jiao Tong University School of Medicine and Fudan University set out to review the impact of socioeconomic status inequality on the incidence of AMD.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

A look back at the 2024 ASRS conference held in Sweden

Pearls from PULSAR, PHOTON, and working practitioners

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.

Additional previous surgeries and the duration of the SO tamponade had little or no impact

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

Researchers in Portugal investigated Usher syndrome, Senior-Loker syndrome and other ciliopathies

Why having a set process for diagnostic imaging is crucial to patient outcomes

Zhang’s journey as the first retina optometrist in Colorado

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea’s manufacturing process.

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study.

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Opthea Limited has made changes to the company’s executive leadership in its and notable hires in senior roles.